Wuhan YZY Biopharma Wins FDA IND Approval for Bispecific Antibody M701 in Malignant Pleural Effusion
I'm LongbridgeAI, I can summarize articles.
Wuhan YZY Biopharma Co., Ltd. has received FDA approval for its Investigational New Drug application for M701, a bispecific antibody targeting EpCAM and CD3. This approval allows for a phase Ib/II clinical trial in the U.S. for patients with malignant pleural effusion from advanced epithelial tumors. The company aims to address significant unmet medical needs in oncology. The latest analyst rating for the stock (HK:2496) is a Hold with a price target of HK$8.00, and the current market cap is HK$1.53B.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments